Lv1
20 积分 2023-10-10 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
1个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
2个月前
已完结
PD1 × VEGF blocking bispecifics for cancer draw big backing
2个月前
已完结
Ivonescimab: First Approval
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
4个月前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
5个月前
已完结
T cell killing does not require the formation of a stable mature immunological synapse
7个月前
已完结
Navigating the clinical challenges of Zolbetuximab in patients with claudin positive advanced gastric cancer
8个月前
已完结
Structural basis of assembly of the human T cell receptor–CD3 complex
8个月前
已完结
皖公网安备34019202002308
